Propranolol and Heart Injury After Breast Cancer Surgery in People With Hypertension or Angina
Tests propranolol for protecting the heart after breast cancer surgery.
Key facts
- Who runs it
- Chang-Ik Yoon
- Where
- Seoul, South KoreaSee the site
- Trial code
- NCT07583134
- KCT0011912
- Registry title
- Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 100 people, planned
- Started
- 26 May 2026
- Expected to end
- 24 May 2033
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- propranolol
- Usual Care
- Record updated
- 15 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 20 to 70 with early breast cancer who also have high blood pressure or angina needing medication. It tests propranolol to prevent heart injury after surgery.
- Age
- 20 to 70 years
- Sex
- Women only
- Disease stage
- Breast cancer on one side, operable, Stage I-III, ECOG performance status 0-1. Also high blood pressure or angina that needs medication.
- Earlier treatment
- Must not have taken beta-blockers in the 30 days before screening. Must be scheduled for standard treatment after surgery.
Main reasons for not taking part
- Cancer that has spread to distant parts of the body
- Other heart diseases besides high blood pressure or angina
- Moderate to severe asthma or COPD
- Pregnant or breastfeeding
- Systolic blood pressure under 100 mmHg or heart rate under 55 beats per minute
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Female patients aged 20 to 70 years
- Patients diagnosed with hypertension or angina who require medication
- Patients diagnosed with unilateral, resectable primary breast cancer (ICD-10: C50), Stage I-III
- ECOG performance status of 0-1
- Patients scheduled to receive standard postoperative treatment (including adjuvant radiotherapy
- Patients who voluntarily decide to participate and sign the written informed consent form
Who cannot take part
- Patients who have received β-blockers within 30 days prior to screening
- Patients with active infectious diseases, autoimmune diseases (including specific rheumatic diseases), coagulation disorders, or cardiovascular diseases other than hypertension or angina pectoris
- Patients with moderate to severe asthma or chronic obstructive pulmonary disease (COPD)
- Patients with a history of malignancy within the past 5 years
- Patients with systolic blood pressure < 100 mmHg or heart rate < 55 beats per minute
- Patients with clinically significant hepatic, hematologic, or renal dysfunction, defined as any of the following:; ① ANC <1,500/mm3; Platelets <100,000/mm3; Hb <9 g/dL; AST and ALT > 2.5 x upper limit of normal (ULN) ⑤ Alkaline phosphatase > 2.5 x ULN ⑥ Total bilirubin > 1 x ULN ⑦ Serum creatinine >1.5 x ULN or estimated creatinine clearance < 60 mL/min (as calculated using the method standard for the institution)
- Patients with distant metastases
- Patients who are pregnant or breastfeeding at the time of enrollment
- Patients for whom data collection is considered difficult at the discretion of the investigator
- Patients who are unable to understand or complete study questionnaires
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 70 years old?
Where in South Korea
- Seoul St. Mary's Hospital, The Catholic University of KoreaSeoul, South KoreaContact: Jinah Lee, MDNot yet recruiting
About the trial
What the trial wants to find out
This study aims to evaluate the impact of using propranolol, a non-selective beta-blocker, on preventing myocardial injury after non-cardiac surgery (MINS) in breast cancer patients who also have hypertension or angina. Stress from surgery and anesthesia can increase sympathetic activity and inflammation, which may lead to heart stress. This pragmatic clinical trial will compare patients who are prescribed propranolol as part of their routine care with those who are not. Researchers will analyze blood samples and surgical tissues collected during normal treatment to observe changes in heart health and the tumor microenvironment.
The 2 groups in the trial
- Propranolol GroupTreatment being tested
Participants with hypertension or angina undergoing breast cancer surgery will receive Propranolol (dosage based on clinical indication) for at least 14 days before surgery until the morning of the operation.
Treatment: propranolol
- Non-Propranolol Group (Usual Care)Existing treatment, for comparison
Participants will receive standard clinical care for hypertension or angina without the use of Propranolol or other beta-blockers before surgery
Treatment: Usual Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pragmatic Clinical Trial to Evaluate the Impact of Clinical Propranolol Strategies on Myocardial Injury After Non-cardiac Surgery (MINS) in Patients Undergoing Breast Cancer Surgery With Hypertension or Angina
- Plain-language title
- Propranolol and Heart Injury After Breast Cancer Surgery in People With Hypertension or AnginaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07583134, who can take part
- Record updated
- 15 May 2026